ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

1:45PM-2:00PM: Abstract Number: 0780

Baseline Pharmacodynamic Markers and Response to Emapalumab in Children and Adults with Macrophage Activation Syndrome (MAS) in Still’s Disease: Results from a Pooled Analysis of Two Prospective Trials

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

1:45PM-2:00PM: Abstract Number: 0804

Comparative Risk of All-Cause Mortality with Belimumab versus Oral Immunosuppressant Use in Patients with Non-Renal Systemic Lupus Erythematosus

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

1:45PM-2:00PM: Abstract Number: 0798

Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

1:45PM-2:00PM: Abstract Number: 0792

Real-World Assessment of Glucocorticoid-Induced Skin Toxicity in Individuals with Rheumatic Diseases

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

1:45PM-2:00PM: Abstract Number: 0810

Spatial Transcriptomic-based Phenotyping of the Fibroblast Niches in Systemic Sclerosis-associated Primary Heart Involvement

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

2:00PM-2:15PM: Abstract Number: 0799

Citrullination of neutrophil serine proteases enhances proteolytic activity, stability and autoantigenicity in Rheumatoid Arthritis

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

2:00PM-2:15PM: Abstract Number: 0781

Comprehensive mass cytometry analyses of disease-related cells in adult-onset Still’s disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

2:00PM-2:15PM: Abstract Number: 0805

Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

2:00PM-2:15PM: Abstract Number: 0811

SSc Skin Cell Atlas: a Scalable Web Portal for scRNA-Seq Analysis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

2:00PM-2:15PM: Abstract Number: 0787

The Cost-effectiveness of Physical Therapy for Patients with Meniscal Tear and Osteoarthritis

Abstracts: Orthopedics, Low Back Pain, & Rehabilitation (0783–0788)

2:00PM-2:15PM: Abstract Number: 0793

The weight of the past: how trauma and resilience shape medication adherence in SLE

Abstracts: Patient Outcomes, Preferences, & Attitudes (0789–0794)

2:15PM-2:30PM: Abstract Number: 0812

Anti-CD206 CAR T Cell Immunotherapy Mitigates Dermal Pathology in Systemic Sclerosis

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science (0807–0812)

2:15PM-2:30PM: Abstract Number: 0806

Comparative Risk of Infection-Related Complications in Systemic Lupus Erythematosus Patients Treated with Anifrolumab versus Belimumab: A Target Trial Emulation

Abstracts: Systemic Lupus Erythematosus – Treatment I (0801–0806)

2:15PM-2:30PM: Abstract Number: 0782

Expansion of T-bet⁺ Age-Associated B Cells Is Associated with Clinical Complications in Still’s Disease

Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases I: Focus on Auto-Inflammatory Diseases (0777–0782)

2:15PM-2:30PM: Abstract Number: 0800

Microbiota-Derived Indole Promotes Collagen-Induced Arthritis Type-17 Immunity through Intestinal Dendritic Cell Cytokine Production

Abstracts: Rheumatoid Arthritis – Etiology and Pathogenesis (0795–0800)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].